Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Saved in:
| Title: | Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study. |
|---|---|
| Authors: | Saberi Hosnijeh F; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands. Electronic address: f.saberihosnijeh@erasmusmc.nl., van der Straten L; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Kater AP; Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands., van Oers MHJ; Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center, Amsterdam, The Netherlands., Posthuma WFM; Department of Internal Medicine, Reinier de Graaf Hospital, Delft, The Netherlands; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Chamuleau MED; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands., Bellido M; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Doorduijn JK; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Gelder M; Department of Hematology, University Medical Center, Maastricht, The Netherlands., Hoogendoorn M; Department of Internal Medicine, Medical Center, Leeuwarden, The Netherlands., de Boer F; Department of Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands., Te Raa GD; Department of Internal Medicine, Gelderland Valley Hospital, Ede, The Netherlands., Kerst JM; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Marijt EWA; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Raymakers RAP; Department of Hematology, University Medical Center, Utrecht, The Netherlands., Koene HR; Department of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands., Schaafsma MR; Department of Hematology, Medical Spectrum Twente, Enschede, The Netherlands., Dobber JA; Laboratory Special Hematology, Academic Medical Center, Amsterdam, The Netherlands., Tonino SH; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands., Kersting SS; Department of Hematology, Haga Hospital, The Hague, The Netherlands., Langerak AW; Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands. |
| Source: | Experimental hematology [Exp Hematol] 2020 Sep; Vol. 89, pp. 55-60.e6. Date of Electronic Publication: 2020 Aug 08. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Elsevier Science Inc Country of Publication: Netherlands NLM ID: 0402313 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2399 (Electronic) Linking ISSN: 0301472X NLM ISO Abbreviation: Exp Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
